Polycythemia vera (PV) associated pruritus is recognized as the most excruciating aspect of the disease. However, knowledge of pathophysiology, frequency, and precise character of PV-associated pruritus is limited. Ruxolitinib presented an encouraging and promising outcome in managing PV-related pruritus, especially in patients with symptoms refractory to other treatment modalities.